Literature DB >> 21770483

Addressing the challenge for well informed and consistent reimbursement decisions: the case for reference models.

Hossein Haji Ali Afzali, Jonathan Karnon.   

Abstract

Mesh：

Year:  2011        PMID： 21770483     DOI： 10.2165/11593000-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  5 in total

Review 1.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 3.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Authors:  Z Philips; L Ginnelly; M Sculpher; K Claxton; S Golder; R Riemsma; N Woolacoot; J Glanville
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014

Review 4.  Health economics, economic evaluation, and glaucoma.

Authors:  Gisela Kobelt
Journal:  J Glaucoma       Date:  2002-12       Impact factor: 2.503

5.  Modelling in economic evaluation: an unavoidable fact of life.

Authors:  M J Buxton; M F Drummond; B A Van Hout; R L Prince; T A Sheldon; T Szucs; M Vray
Journal:  Health Econ       Date:  1997 May-Jun       Impact factor: 3.046
  5 in total
  8 in total

1.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

2.  Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.

Authors:  Gerardus W J Frederix; Hossein Haji Ali Afzali; Erik J Dasbach; Robyn L Ward
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

3.  Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.

Authors:  Anthony J Hatswell; Fleur Chandler
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

Review 4.  HTA agencies facing model biases: the case of type 2 diabetes.

Authors:  Véronique Raimond; Jean-Michel Josselin; Lise Rochaix
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

5.  Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.

Authors:  Eric Q Wu; Zheng-Yi Zhou; Jipan Xie; Cinzia Metallo; Praveen Thokala
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 6.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

7.  Benefits, Challenges and Potential Strategies of Open Source Health Economic Models.

Authors:  William C N Dunlop; Nicola Mason; James Kenworthy; Ron L Akehurst
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

8.  Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations.

Authors:  Geert W J Frederix
Journal:  Pharmacoecon Open       Date:  2019-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.